Apr 2026
Inspirations
Spark Sessions by InVirtuoLabs
A conversation series where scientists and entrepreneurs discuss the ideas, breakthroughs and people shaping the future of drug discovery.
Home / News
News
Research breakthroughs, partnerships and key moments. Four streams, one ongoing story.
Feb 2026
Collaborations
Helsinn & InVirtuoLabs sign a strategic collaboration in AI-driven drug discovery
Helsinn provides access to a proprietary compound library while InVirtuoLabs applies InVirtuoGEN to design and optimize novel drug candidates for preclinical development.
Feb 2026
Collaborations
InVirtuoLabs to lead €2.3M Eurostars grant project NeuroSpark
Startupticker covers the Eurostars-funded NeuroSpark project, a 36-month initiative advancing AI-driven Virtual Cell Models for neurodegeneration drug research.
Jan 2026
Collaborations
InVirtuoLabs receives a €2.3M Eurostars grant to advance Virtual Cell Models
A 36-month Eurostars-funded project to develop AI-driven "digital twins" of diseased cells, targeting Spinocerebellar Ataxia Type 3 and broader neurodegenerative disorders.
Oct 2025
Breakthroughs
InVirtuoGen: open-source results and pretrained checkpoints
Pretrained checkpoints, benchmarks and reproducible results for InVirtuoGEN released on GitHub — enabling full reproducibility of our state-of-the-art generative chemistry model.
Oct 2025
Breakthroughs
InVirtuoLabs unveils InVirtuoGEN: the AI model that outperforms NVIDIA on all benchmarks
InVirtuoGEN surpasses NVIDIA's proprietary model on every benchmark, achieving up to 35% improvement in de novo generation and 20–30% better binding scores in lead optimization.
Sep 2025
Breakthroughs
Refine Drugs, Don't Complete Them: our paper on discrete flows for drug discovery
The foundational research behind InVirtuoGEN — a discrete flow generative model that shifts molecular design from completion to refinement. Accepted at the NeurIPS AI for Drug Discovery Workshop.
Jul 2025
Inspirations
Meet Gianvito Grasso, CEO of InVirtuoLabs
An interview by the Swiss Startup Association on our founding vision, how AI and physics-based simulations are transforming drug discovery, and what's next for InVirtuoLabs.
Feb 2025
Milestones
InVirtuoLabs secures €2.85 million to accelerate AI-driven drug discovery
The Swiss biotech startup closes its first funding round, enabling rapid expansion of the Next Generation Virtual Lab platform and strategic collaborations with pharma partners worldwide.
Dec 2024
Milestones
Boldbrain 2024 Winners
InVirtuoLabs wins first prize at the Boldbrain Startup Challenge, an acceleration program for innovative ideas organized by the Agire Foundation in collaboration with the USI Startup Centre.
Sep 2024
Collaborations
Innosuisse's Flagship Initiative
InVirtuoLabs is part of ORION, an Innosuisse Flagship project developing an AI-driven microfactory for patient-specific tumor models — enabling personalized cancer therapies and accelerating biomarker discovery, drug development and precision oncology.